Prime Medicine, Inc. (PRME)
NASDAQ
Closed
Sep 18, 2026
Day's Range
3.0452 wk Range
2.67Overview - PRME - Prime Medicine, Inc.
Key Statistics
Valuation
Enterprise Value
613.38M
P/E (Trailing)
‪-2.31‬
P/E (Forward)
‪-3.59‬
PEG Ratio
‪0.05‬
Price / Sales (TTM)
‪141.38‬
Price / Book
‪14.11‬
EV / EBITDA
‪-3.24‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-3,750.86%‬
Return on Assets
‪-46.52%‬
Return on Equity
‪-373.28%‬
Ownership
Shares Outstanding
180.73M
Float
112.25M
Short % of Shares Outstanding
‪25.91%‬
Held by Insiders
‪23.66%‬
Held by Institutions
‪71.20%‬
Price stats
Beta
‪2.34‬
50-Day Avg
‪3.38‬
200-Day Avg
‪3.54‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
14 analysts
Average price target
‪$ 7.30‬Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - PRME - Prime Medicine, Inc.
Peers - PRME - Prime Medicine, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- PRMENASDAQPrime Medicine, Inc.567.70MMarket Cap-28.11%52-week change-2.31P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - PRME - Prime Medicine, Inc.
About
Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA. The company is building therapies intended to address diseases caused by defined genetic alterations, with research programs…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
